Kellier N, Krohn K, Gilsenan AW, Harris DH, Andrews EB, Massica D. Forteo voluntary patient registry: 3-Year progress on a prospective osteosarcoma surveillance study. Poster presented at the American Society for Bone and Mineral Research Annual Meeting; October 6, 2013.
Gilsenan AW, Midkiff KD, Andrews EB, Von Scheele BG, Masica D, Ceberg J. Multinational collaboration: a long-term surveillance program for osteosarcoma and potential exposure to teriparatide. Presented at the 36th meeting of the Scandinavian Sarcoma Group; October 2013.
Midkiff KD, Von Scheele BG, Gilsenan AW, Ceberg J, Alvegård T. Progress update for the postmarketing adult osteosarcoma surveillance study in five Nordic countries. Poster presented at the 36th meeting of the Scandinavian Sarcoma Group; October 2013.
Kruse-Jarres R, Gilsenan AW, Spears J, Kaye JA. Prospective study of plasma-derived factor VIII/vWF in immune tolerance induction therapy: the SPIRIT registry. Poster presented at the Annual Meeting of the National Hemophilia Foundation; October 2013.
Harris DH, Midkiff K, Gilsenan A, Kellier N, Masica D, Andrews E. Eight-year results from the US osteosarcoma surveillance study. Poster presented at the 29th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2013. Montreal.
Gilsenan AW, Harris DH, Midkiff KD, Andrews EB, Kellier N, Masica D. Approaches to long-term surveillance for rare cancer events. Poster presented at the 29th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 25, 2013. Montreal, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2013 Aug; 22(Suppl 1):218-9.
Harris DH, Gilsenan AW, Midkiff KD, Harding AA. Navigating the registry-specific approval process for a long-term drug safety surveillance study. Presented at the NAACCR - North American Association of Central Cancer Registries; June 2013.
Midkiff KD, Harris DH, Gilsenan AW, Powell GL. Variations among cancer registries in accessing patients for a drug safety surveillance study. Poster presented at the NAACCR; June 2013.
Gilsenan AW, Andrews EB. Considerations and strategies for benefit-risk assessment in the real-world setting. In: Sashegyi A, Felli J, Noel R, editors. Benefit-risk assessment in pharmaceutical research and development. 1st ed. Boca Raton: United States. CRC Press; 2013. p.153-64.
Gilsenan AW, Harris DH, Midkiff KD, Andrews EB, Massica D. Seeing the big picture in long-term surveillance for rare events. Presented at the North American Association of Central Cancer Registries Annual Conference; 2013.
Mintz M, Gilsenan AW, Bui CL, Ziemiecki R, Stanford RH, Lincourt W, Ortega H. Assessment of asthma control in primary care. Curr Med Res Opin. 2009 Oct 1;25(10):2523-31.
Gilsenan A, Stanford RH, Bui C, Ziemiecki RM, Ortega H. Predictors of uncontrolled asthma in adult and pediatric patients: results from the asthma control characteristics and prevalence survey study (ACCESS). Poster presented at the 25th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2009. Providence, RI.
Gilsenan A, Andrews EB, Calingaert B, Crozier DA, Vanderpuije A. Evaluation of current risk evaluation and mitigation strategies. Poster presented at the 25th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 16, 2009. Providence, RI.
Midkiff KD, Gilsenan AW, Martin RD, Wu Y, Masica D, Andrews EB. The impact of patient access on post marketing drug safety studies using cancer registry data. Poster presented at the 25th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2009. Providence, RI. [abstract] Pharmacoepidemiol Drug Saf. 2009 Aug 14; 18(Suppl 1):S169. doi: 10.1002/pds.1806
Gilsenan AW, Andrews EB, Martin R, Midkiff KD. Charting a new course: the critical role of cancer registries in the science of drug safety. Poster presented at the North American Association of Central Cancer Registries Annual Meeting; June 2009.
Midkiff KD, Gilsenan AW, Martin RD, Andrews EB, Wu Y, Masica D. The new world in cancer surveillance: accommodating patient privacy and drug safety studies. Presented at the NAACCR; June 2009.
Midkiff KD, Martin RD, Gilsenan AW, Masica D, Andrews EB. New directions in using cancer registry data 5–year results from a patient drug safety surveillance study of adult osteosarcoma. Presented at the North American Association of Central Cancer Registries Annual Meeting; June 2009.
Midkiff KD, Gilsenan AW, Martin RD, Wu Y, Masica N, Andrews EB. Characteristics of patients in a post marketing osteosarcoma surveillance study. Presented at the 34th Meeting of the Scandinavian Sarcoma Group; May 2009.
Zhou X, Nonnemaker J, Sherrill B, Gilsenan AW, Coste F, West R. Attempts to quit smoking and relapse: factors associated with success or failure from the ATTEMPT cohort study. Addict Behav. 2009 Apr 1;34(4):365-73.
Stanford RH, Gilsenan AW, Lincourt W, Lankevich C, Stempel DA, Ziemiecki RM, Ortega HG. Predictors of asthma control: results from the asthma control characteristics and prevalence survey study (ACCESS). Presented at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology; March 2009. Washington, DC.
Stanford RH, Gilsenan AW, Lincourt W, Lankevich C, Ortega HG. The effect of body mass index on asthma control: results from the asthma control characteristics and prevalence survey study (ACCESS). Presented at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology; March 2009. Washington, DC.
Hansen RA, Song L, Moore CG, Gilsenan AW, Kim MM, Calloway MO, Murray MD. Effect of ropinirole on sleep outcomes in patients with restless legs syndrome: meta-analysis of pooled individual patient data from randomized controlled trials. Pharmacotherapy. 2009 Mar;29(3):255-62.
Von Scheele BG, Martin RD, Gilsenan AW, Ceberg J, Andrews EB, Masica D, Alvegård T. The European postmarketing adult osteosarcoma surveillance study characteristics of patients: a preliminary report. Acta Orthop. 2009;80:67-74.